The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Abstract
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3′-azido-3′-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4 + HeLa cells. Fifty percent inhibitory dose (ID 50 ) values of 18 isolates from untreated individuals ranged between 0.01 μ M and 0.05 μ M . In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID 50 or ID 95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in ID 50 . The latter isolates were also insensitive to 3′-azido-2′,3′-dideoxyuridine; however, the isolates were still sensitive to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-2′,3′-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a clinical trial, its dramatic short-term effects in delaying the death of AIDS patients (109) led to its rapid approval for use, although the virus rebounded after a few months due to the appearance of mutations in RT that render it AZT resistant (110).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [110]
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Klecker, R. W., Collins, J. M., Yarchoan, R., Thomas, R., Jenkins, J. F., Broder, S., & Myers, C. E. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.49 · Cited by 381
Site-specific mutagenesis of AIDS virus reverse transcriptase
Larder, B. A., Purifoy, D. J. M., Powell, K. L., & Darby, G. (1987) · Nature · doi:10.1038/327716a0 · Cited by 312
Self-citationDevelopment of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
Chesebro, B., & Wehrly, K. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3779-3788.1988 · Cited by 304
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Self-citationISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY
Burns, W., Santos, G., Saral, R., Laskin, O., Lietman, P., Mclaren, C., & Barry, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91620-8 · Cited by 240
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Self-citation
Cited by
Items 501–600 of 1,000
YouCanTeach an Old Dog New Tricks: How AIDS Trials Are Pioneering New Strategies
Merigan, T. C. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231911 · Cited by 48
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Manasa, J., Danaviah, S., Pillay, S., Padayachee, P., Mthiyane, H., Mkhize, C., Lessells, R. J., Seebregts, C. J., de Wit, T. F. R., Viljoen, J., et al. (2014) · Journal of Visualized Experiments · doi:10.3791/51242-v · Cited by 47
Mousseau, G., Aneja, R., Clementz, M. A., Mediouni, S., Lima, N. S., Haregot, A., Kessing, C. F., Jablonski, J. A., Thenin-Houssier, S., Nagarsheth, N., et al. (2019) · mBio · doi:10.1128/mbio.01750-18 · Cited by 47
Inhibition of human immunodeficiency virus type I replication by derivatives of gossypol
Royer, R. E., MILLS, R., Deck, L. M., MERTZ, G. J., & VANDERJAGT, D. (1991) · Pharmacological Research · doi:10.1016/1043-6618(91)90045-y · Cited by 47
Erice, A., Balfour, H. H., Myers, D. E., Leske, V. L., Sannerud, K. J., Kuebelbeck, V. M., Irvin, J. D., & Uckun, F. M. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.4.835 · Cited by 47
Non-nucleoside inhibitors of HIV-1 reverse transcriptase
Young, S. D. (1993) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171661 · Cited by 47
Liem, S. E., Ramezani, A., Li, X., & Joshi, S. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.5-625 · Cited by 47
Brun‐Vézinet, F., Ingrand, D., Deforges, L., Gochi, K., Ferchal, F., Schmitt, M., Jung, M., Masquelier, B., Aubert, J., Buffet‐Janvresse, C., et al. (1992) · Journal of Virological Methods · doi:10.1016/0166-0934(92)90045-f · Cited by 47
Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives
Baba, M., Shigeta, S., Tanaka, H., Miyasaka, T., Ubasawa, M., Umezu, K., Walker, R. T., Pauwels, R., & Clercq, E. D. (1992) · Antiviral Research · doi:10.1016/0166-3542(92)90021-v · Cited by 47
Grand, R. L., Clayette, P., Noack, O., Vaslin, B., Théodoro, F., Michel, G., Roques, P., & Dormont, D. (1994) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1994.10.1279 · Cited by 47
The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate
Julias, J. G., Kim, T., Arnold, G., & Pathak, V. K. (1997) · Journal of Virology · doi:10.1128/jvi.71.6.4254-4263.1997 · Cited by 47
A novel method for determining the inhibitory potential of anti-HIV drugs
Shen, L., Rabi, S. A., & Siliciano, R. F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.003 · Cited by 46
Quan, Y., BRENNER, B. G., Oliveira, M., & Wainberg, M. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.747-754.2003 · Cited by 46
Choi, H. J., Dinarello, C. A., & Shapiro, L. (2001) · The Journal of Infectious Diseases · doi:10.1086/322805 · Cited by 46
Brennan, T., TAYLOR, D., BRIDGES, C. G., LEYDA, J., & Tyms, A. S. (1995) · Antiviral Research · doi:10.1016/0166-3542(94)00074-i · Cited by 46
Sluis‐Cremer, N., Arion, D., Parikh, U. M., Koontz, D. L., Schinazi, R. F., Mellors, J. W., & Parniak, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503166200 · Cited by 46
Antiviral Therapy in Human Immunodeficiency Virus Infection
Sandström, E. (1989) · Drugs · doi:10.2165/00003495-198938030-00005 · Cited by 46
Resistance, Drug Failure, and Disease Progression
Richman, D. D. (1994) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1994.10.901 · Cited by 46
Self-citationBerman, E., Duigou-Osterndorf, R., Krown, S. E., Fanucchi, M., Chou, J. H., Hirsch, M., Clarkson, B., & Chou, T. (1989) · Blood · doi:10.1182/blood.v74.4.1281.1281 · Cited by 46
Resistance of Human Immunodeficiency Virus Type 1 to Antiretroviral Agents: A Review
Erice, A., & Balfour, H. H. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.149 · Cited by 46
McLeod, G. X., McGrath, J. M., Ladd, E. A., & Sm, H. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.5.920 · Cited by 46
Martrus, G., Niehrs, A., Cornelis, R., Rechtien, A., García-Beltrán, W. F., Lütgehetmann, M., Hoffmann, C., & Altfeld, M. A. (2016) · Journal of Virology · doi:10.1128/jvi.01448-16 · Cited by 45
Kaye, S., Comber, E., Tenant‐Flowers, M., & Loveday, C. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.1221 · Cited by 45
Three New Potent HIV-1 Inhibitors from Myxobacteria
Jurkiewicz, E., Jansen, R., Kunze, B., Trowitzsch‐Kienast, W., Forche, E., Reichenbach, H., Höfle, G., & Hunsmann, G. (1992) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029200300401 · Cited by 45
Snoeck, R., Andreï, G., Neyts, J. H., Schols, D., Cools, M., Balzarini, J. M., & Clercq, E. D. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90028-h · Cited by 45
HIV Inhibitors: Problems and Reality
Tőzsér, J. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03909.x · Cited by 45
Keating, M. R. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61319-6 · Cited by 45
A novel class of 1,3-oxathiolane nucleoside analogues having potent anti-HIV activity
Belleau, B., Brasili, L., Chan, L. C., Marco, M. P. D., Zacharie, B., Nguyen‐Ba, N., Jenkinson, H. J., Coates, J. A. V., & Cameron, J. M. (1993) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)80050-5 · Cited by 45
Drug-Resistant HIV-1: The Virus Strikes Back
Mayers, D. L. (1998) · JAMA · doi:10.1001/jama.279.24.2000 · Cited by 45
Das, K., Balzarini, J. M., Miller, M. T., Maguire, A. R., DeStefano, J. J., & Arnold, E. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00187 · Cited by 44
Antiretroviral (ARV) drug resistance in the developing world.
Shekelle, P., Maglione, M., Geotz, M. B., Wagner, G. J., Wang, Z., Hilton, L. G., Carter, J. M., Chen, S. E., Tringle, C., Mojica, W., et al. (2007) · PubMed · Cited by 44
Jeeninga, R. E., Keulen, W., Boucher, C. A., Sanders, R. W., & Berkhout, B. (2001) · Virology · doi:10.1006/viro.2001.0888 · Cited by 44
Interferon alpha in the treatment of AIDS‐related Kaposi's sarcoma
Mitsuyasu, R. T. (1991) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08124.x · Cited by 44
The independent effect of drug resistance on T cell activation in HIV infection
Hunt, P. W., Deeks, S. G., Bangsberg, D. R., Moss, A. R., Sinclair, E., Liegler, T. J., Bates, M. P., Tsao, G. J., Lampiris, H. W., Hoh, R., et al. (2006) · AIDS · doi:10.1097/01.aids.0000216369.30948.18 · Cited by 44
Mechanisms of HIV-1 drug resistance
Larder, B. A. (2001) · AIDS · doi:10.1097/00002030-200100005-00005 · Cited by 44
Self-citationStürmer, M., Staszewski, S., Doerr, H.-W., Larder, B. A., Bloor, S., & Hertogs, K. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.54-61.2003 · Cited by 44
Self-citationInitial Clinical Experience with Dideoxynucleosides as Single Agents and in Combination Therapy
Yarchoan, R., Pluda, J. M., Perno, C. F., Mitsuya, H., Thomas, R. V., Wyvill, K., & Broder, S. E. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb17853.x · Cited by 44
Imamichi, T., Sinha, T., Imamichi, H., Zhang, Y., Metcalf, J. A., Falloon, J., & Lane, H. C. (2000) · Journal of Virology · doi:10.1128/jvi.74.2.1023-1028.2000 · Cited by 44
Synthesis of enantiomerically pure cyclopropyl carbocyclic nucleosides
Zhao, Y., Yang, T., Lee, M., Chun, B. K., Du, J., Schinazi, R. F., Lee, D., Newton, M. G., & Chu, C. K. (1994) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)73511-8 · Cited by 44
Jacobson, M. A., C. van der Horst, Causey, D., Dehlinger, M., Hafner, R., & MILLS, J. S. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.6.1219 · Cited by 44
Bacheler, L. T., Paul, M. L., Otto, M. J., Jadhav, P., Stone, B. A., & Miller, J. A. (1994) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029400500208 · Cited by 44
Monie, D., Simmons, R. P., Nettles, R. E., Kieffer, T. L., Zhou, Y., Zhang, H., Karmon, S. L., Ingersoll, R., Chadwick, K. R., Zhang, H., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5185-5202.2005 · Cited by 43
Ntemgwa, M. L., Wainberg, M. A., Oliveira, M., Moisi, D. D., LALONDE, R. G., Micheli, V., & BRENNER, B. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00646-07 · Cited by 43
Running with Scissors: Using Antiretroviral Therapy without Monitoring Viral Load
Smith, D. M., & Schooley, R. T. (2008) · Clinical Infectious Diseases · doi:10.1086/587110 · Cited by 43
Götte, M., & Wainberg, M. A. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0126 · Cited by 43
Closing in on HIV drug resistance.
Larder, B. A., & STAMMERS, D. K. (1999) · Nature Structural Biology · doi:10.1038/5787 · Cited by 43
Self-citationDeminie, C. A., Bechtold, C. M., Stock, D. A., Alam, M., Djang, F., Balch, A. H., Chou, T., Prichard, M. N., Colonno, R. J., & Lin, P. F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.6.1346 · Cited by 43
Atkinson, B. F., Isaacson, J. D., Knowles, M. R., Mazabel, E., & Patick, A. K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315726 · Cited by 43
Zheng, J. J., Wu, S. T., & Emm, T. A. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(01)00332-2 · Cited by 42
Cox, S. W., Aperia, K., Albert, J., & Wahrén, B. (1994) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1994.10.1725 · Cited by 42
The specificity of the HIV-1 protease
Pettit, S. C., Michael, S. F., & Swanstrom, R. I. (1993) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171656 · Cited by 42
Moyle, G. J. (1996) · Drugs · doi:10.2165/00003495-199652020-00002 · Cited by 42
Rooke, R., Tremblay, M., & Wainberg, M. A. (1990) · Virology · doi:10.1016/0042-6822(90)90245-m · Cited by 42
Borroto–Esoda, K., Waters, J. M., Bae, A. S., Harris, J. L., Hinkle, J. E., Quinn, J., & Rousseau, F. (2007) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.0310 · Cited by 41
Zhou, P., Goldstein, S. C., Devadas, K., Tewari, D., & Notkins, A. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1489 · Cited by 41
Menéndez‐Arias, L., Matamoros, T., & Cases‐González, C. E. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873608 · Cited by 41
A stochastic model for primary HIV infection: optimal timing of therapy
Ribeiro, R. M., & Bonhoeffer, S. (1999) · AIDS · doi:10.1097/00002030-199902250-00007 · Cited by 41
Salomón, H., Belmonte, A. R., Nguyen, K. N. T., Gu, Z., Gelfand, M. M., & Wainberg, M. A. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.8.2000-2002.1994 · Cited by 41
Treatment of AIDS with combinations of antiretroviral agents
Merigan, T. C. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90405-m · Cited by 41
Nucleoside Reverse Transcriptase Inhibitor Resistance
Loveday, C. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200103011-00003 · Cited by 41
Treatment of AIDS and AIDS-Related Complex with 2′,3′-Dideoxyinosine Given Once Daily
Cooley, T. P., Kunches, L. M., Saunders, C. A., Perkins, C. J., Kelley, S. L., McLaren, C., McCaffrey, R. P., & Liebman, H. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_5.s552 · Cited by 41
Polis, M. A., DeSmet, M. D., Baird, B., Mellow, S. D., Falloon, J., Davey, R. T., Kovacs, J. A., Palestine, A. G., Nussenblatt, R. B., Masur, H., et al. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90180-w · Cited by 41
Richman, D. D., Little, S. J., Smith, D. M., Wrin, T., Petropoulos, C. J., & Wong, J. K. (2004) · PubMed · Cited by 40
Self-citationPatents on SELEX and Therapeutic Aptamers
Dua, P., Kim, S., & Lee, D.-K. (2008) · Recent Patents on DNA & Gene Sequences · doi:10.2174/187221508786241710 · Cited by 40
Oh, K., Lee, C., Kim, Y.-S., Eo, S. K., & Han, S.-S. (2000) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(00)00254-3 · Cited by 40
Rezende, L. F., & Prasad, V. R. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.025 · Cited by 40
Ibe, S., Shibata, N., Utsumi, M., & Kaneda, T. (2003) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2003.tb02788.x · Cited by 40
Synthesis of ()-2′-oxa-carbocyclic-2′,3′-dideoxynucleosides as potential anti-HIV agents
Bamford, M. J., Humber, D. C., & Storer, R. (1991) · Tetrahedron Letters · doi:10.1016/0040-4039(91)80873-5 · Cited by 40
Pincus, S. H., & Wehrly, K. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/162.6.1233 · Cited by 40
Husson, R. N., Shirasaka, T., BUTLER, K. M., Pizzo, P. A., & Mitsuya, H. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81530-6 · Cited by 40
Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection
Yarchoan, R., Mitsuya, H., & Broder, S. E. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90571-8 · Cited by 40
Lacey, S. F., & Larder, B. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.5.3421-3424.1994 · Cited by 40
Self-citationHolodniy, M., Mole, L. A., Margolis, D. M., Moss, J., Dong, H., Boyer, E., Urdea, M. S., Kolberg, J. A., & Eastman, S. W. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3510-3516.1995 · Cited by 40
Open access clinic providing HIV-I antibody results on day of testing: the first twelve months.
Squire, S. B., Elford, J., Bor, R. J., Tilsed, G., Salt, H., Bagdades, E. K., Janossy, G., Griffiths, P. D., & Johnson, M. A. (1991) · BMJ · doi:10.1136/bmj.302.6789.1383 · Cited by 40
Bálint, G. S. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00101-7 · Cited by 39
Rachlis, A. (1990) · Europe PMC (PubMed Central) · Cited by 39
Phillips, A. N., Youle, M. S., Johnson, M. A., & Loveday, C. (2001) · AIDS · doi:10.1097/00002030-200111230-00001 · Cited by 39
Puchhammer‐Stöckl, E., Steininger, C., Geringer, E., & Fx, H. (2002) · HIV Medicine · doi:10.1046/j.1468-1293.2002.00116.x · Cited by 39
Edlin, B. R., Clair, M. H. S., Pitha, P. M., Whaling, S. M., King, D. M., Bitran, J. D., & Weinstein, R. A. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-457 · Cited by 39
Busso, M. E., & Resnick, L. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.10.1991 · Cited by 39
Berglund, O., Engman, K., Ehrnst, A., Andersson, J., Lidman, K., Åkerlund, B., Sönnerborg, A. B., & Strannegård, Ö. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.4.710 · Cited by 39
Deibel, M. R., McQuade, T. J., Brunner, D. P., & Tarpley, W. G. (1990) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1990.6.329 · Cited by 39
Monitoring patients with HIV disease
HELBERT, M., & Breuer, J. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.4.266 · Cited by 38
HIV and reverse transcriptase inhibition by tannins
Kilkuskie, R. E., Kashiwada, Y., Nonaka, G.-I., Nishioka, I., Bodner, A. J., Cheng, Y.-C., & Lee, K. (1992) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)80422-9 · Cited by 38
Boal, J. H., Plessinger, M. A., van den Reydt, C., & Miller, R. K. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8046 · Cited by 38
Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase
Higuchi, H., Mori, K., Kato, A., Ohkuma, T., Endo, T., Kaji, H. K., & Kaji, A. (1991) · Antiviral Research · doi:10.1016/0166-3542(91)90067-2 · Cited by 38
Morgan, M. E., Chi, S. C., Murakami, K., Mitsuya, H., & Anderson, B. D. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.10.2156 · Cited by 38
Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a
Negro, F., Baldi, M., Mondardini, A., Leandro, G., Chaneac, M., Manzini, P. M., Abate, M. L., Zahm, F. E., Dastoli, G., Ballare, M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90174-0 · Cited by 38
Edlin, B. R., Weinstein, R. A., Whaling, S. M., Ou, C. Y., Connolly, P. J., Moore, J. L., & Bitran, J. D. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/165.5.793 · Cited by 38
Goldman, M. E., O'Brien, J. A., Ruffing, T. L., Nunberg, J. H., Schleif, W. A., Quintero, J. C., Siegl, P. K. S., HOFFMAN, J. M. J., Smith, A. M., & Emini, E. A. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.5.1019 · Cited by 38
Kim, B. S., & Loeb, L. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.684 · Cited by 38
Horton, C., Dudley, M. N., Kaul, S., Mayer, K. H., Squires, K., Dunkle, L. M., & Anderson, R. E. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.10.2309 · Cited by 38
Antiretroviral Drug Resistance: Mechanisms, Pathogenesis, Clinical Significance
Richman, D. D. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9209-6_35 · Cited by 38
Self-citationFitzgibbon, J. E., Farnham, A. E., Sperber, S. J., Kim, H., & Dubin, D. T. (1993) · Journal of Virology · doi:10.1128/jvi.67.12.7271-7275.1993 · Cited by 38
Mathematical Modelling of Biosystems
Mondaini, R. P., & Pardalos, P. M. (2008) · Springer eBooks · doi:10.1007/978-3-540-76784-8 · Cited by 37
Quan, Y., BRENNER, B. G., Marlink, R., Essex, M., Kurimura, T., & Wainberg, M. A. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203769232548 · Cited by 37
5 Inhibitors of HIV Proteinase
Martin, J. A., Redshaw, S. D., & Thomas, G. J. (1995) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70455-7 · Cited by 37
Hematologic Effects of AIDS Therapies
Pluda, J. M., Mitsuya, H., & Yarchoan, R. (1991) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30438-6 · Cited by 37
Chen, M., Suttmann, R. T., Wu, J. C., & Prisbe, E. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48487-6 · Cited by 37
Mulato, A. S., Lamy, P. D., Miller, M. D., Li, W.-X., Anton, K. E., Hellmann, N. S., & Cherrington, J. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1620 · Cited by 37
Metadata
- Authors
- Larder, B. A., Darby, G., & Richman, D. D.
- Affiliations
- Wellcome Trust (GB)
- University of California San Diego (US)
- ORCID
- Richman, Douglas D.
- Venue
- Science
- Published
- 1989-03-31
- Volume
- 243
- Issue
- 4899
- Pages
- 1731-1734
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086462809
- Cited by
- 1,559
- References
- 22
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 10 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 10 · 2014: 21 · 2013: 13 · 2012: 16
- FWCI
- 157.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HB-6-7019)
- National Institute of Allergy and Infectious Diseases (AI-62548, AI-52578)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV drug resistance, zidovudine resistance, AIDS, AIDS-related complex, antiretroviral therapy, 2',3'-dideoxycytidine, phosphonoformate
- MeSH terms
- Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Drug Resistance, HeLa Cells, HIV, Humans, Microbial Sensitivity Tests, Phosphonoacetic Acid, Viral Plaque Assay, Retroviridae Proteins, Virus Replication, Zidovudine, Dideoxynucleosides, Zalcitabine, HIV Core Protein p24, Foscarnet, Reverse Transcriptase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.